Bristol-Myers Squibb traded at $61.46 this Thursday October 1st, decreasing $0.94 or 1.51 percent since the previous trading session. Looking back, over the last four weeks, Bristol-Myers Squibb lost 9.16 percent. Over the last 12 months, its price rose by 34.40 percent. Looking ahead, we forecast Bristol-Myers Squibb to be priced at 61.50 by the end of this quarter and at 57.60 in one year, according to Trading Economics global macro models projections and analysts expectations.
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.